Reappraisal of ventilator-free days in critical care research

American Journal of Respiratory and Critical Care Medicine

Volumn 200, Issue 7, 2019, Pages 828-836

  Yehya, Nadir ^a,b   Harhay, Michael O ^b   Curley, Martha A Q ^a,b,c   Schoenfeld, David A ^d,e,f   Reeder, Ron W ^g  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute respiratory distress syndrome; ARDS; Competing risk regression; Ventilatorfree days; VFDs

Indexed keywords

METHYLPREDNISOLONE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANALYTIC METHOD; ARTICLE; EXTUBATION; HUMAN; INTENSIVE CARE; NONINVASIVE VENTILATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANK SUM TEST; RISK ASSESSMENT; STUDENT T TEST; TRACHEOSTOMY; VENTILATOR WEANING; ARTIFICIAL VENTILATION; DATA ANALYSIS; METHODOLOGY; REGRESSION ANALYSIS; STATISTICAL ANALYSIS;

AIRWAY EXTUBATION; CRITICAL CARE; DATA ANALYSIS; DATA INTERPRETATION, STATISTICAL; HUMANS; OUTCOME ASSESSMENT, HEALTH CARE; REGRESSION ANALYSIS; RESEARCH DESIGN; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85072746199     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201810-2050CP     Document Type: Article

References (53)

1. Schoenfeld DA, Bernard GR; ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002;30:1772-1777.
2. Schoenfeld DA, Hayden D, Oldmixon C, Ringwood N, Thompson BT. Statistical design and analysis issues for the ARDS Clinical Trials Network: The coordinating center perspective. Clin Invest 2012;2: 275-289.
3. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, et al.; The Antioxidant in ARDS Study Group. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 1997;112: 164-172.
4. Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebocontrolled clinical trial of an aerosolized b2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184:561-568.
5. Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Initial trophic vs full enteral feeding in patients with acute lung injury: The EDEN randomized trial. JAMA 2012;307:795-803.
6. Rice TW, Wheeler AP, Thompson BT, deBoisblanc BP, Steingrub J, Rock P; NIH NHLBI Acute Respiratory Distress Syndrome Network of Investigators. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011;306: 1574-1581.
7. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-1684.
8. Bodet-Contentin L, Frasca D, Tavernier E, Feuillet F, Foucher Y, Giraudeau B. Ventilator-free day outcomes can be misleading. Crit Care Med 2018;46:425-429.
9. Contentin L, Ehrmann S, Giraudeau B. Heterogeneity in the definition of mechanical ventilation duration and ventilator-free days. Am J Respir Crit Care Med 2014;189:998-1002.
10. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149: 818-824.
11. Harhay MO, Ratcliffe SJ, Small DS, Suttner LH, Crowther MJ, Halpern SD. Measuring and analyzing length of stay in critical care trials. Med Care 2019;57:e53-e59.
12. Stapleton RD, Wang BM, Hudson LD, Rubenfeld GD, Caldwell ES, Steinberg KP. Causes and timing of death in patients with ARDS. Chest 2005;128:525-532.
13. Dowell JC, Parvathaneni K, Thomas NJ, Khemani RG, Yehya N. Epidemiology of cause of death in pediatric acute respiratory distress syndrome. Crit Care Med 2018;46:1811-1819.
14. Spragg RG, Bernard GR, Checkley W, Curtis JR, Gajic O, Guyatt G, et al. Beyond mortality: Future clinical research in acute lung injury. Am J Respir Crit Care Med 2010;181:1121-1127.
15. Harhay MO, Wagner J, Ratcliffe SJ, Bronheim RS, Gopal A, Green S, et al. Outcomes and statistical power in adult critical care randomized trials. Am J Respir Crit Care Med 2014;189: 1469-1478.
16. Herridge MS, Chu LM, Matte A, Tomlinson G, Chan L, Thomas C, et al.; RECOVER Program Investigators (Phase 1: Towards RECOVER); Canadian Critical Care Trials Group. The RECOVER program: Disability risk groups and 1-year outcome after 7 or more days of mechanical ventilation. Am J Respir Crit Care Med 2016;194: 831-844.
17. Combes A, Costa MA, Trouillet JL, Baudot J, Mokhtari M, Gibert C, et al. Morbidity, mortality, and quality-of-life outcomes of patients requiring.or=14 days of mechanical ventilation. Crit Care Med 2003;31:1373-1381.
18. Unroe M, Kahn JM, Carson SS, Govert JA, Martinu T, Sathy SJ, et al. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: A cohort study. Ann Intern Med 2010;153:167-175.
19. Hill AD, Fowler RA, Burns KE, Rose L, Pinto RL, Scales DC. Long-term outcomes and health care utilization after prolonged mechanical ventilation. Ann Am Thorac Soc 2017;14: 355-362.
20. Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health outcomes in the presence of competing risks: A review of statistical methods and clinical applications. Med Care 2010;48(Suppl):S96-S105.
21. Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A; Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
22. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564-2575.
23. Manja V, AlBashir S, Guyatt G. Criteria for use of composite end points for competing risks-a systematic survey of the literature with recommendations. J Clin Epidemiol 2017;82:4-11.
24. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials: Systematic review of randomised controlled trials. BMJ 2007;334:786.
25. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al.; Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
26. Yehya N, Keim G, Thomas NJ. Subtypes of pediatric acute respiratory distress syndrome have different predictors of mortality. Intensive Care Med 2018;44:1230-1239.
27. Khemani RG, Smith L, Lopez-Fernandez YM, Kwok J, Morzov R, Klein MJ, et al.; Pediatric Acute Respiratory Distress syndrome Incidence and Epidemiology (PARDIE) Investigators; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Paediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology (PARDIE): An international, observational study. Lancet Respir Med 2019;7:115-128.
28. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al.; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363: 1107-1116.
29. Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al.; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013;368: 2159-2168.
30. Khimenko PL, Barnard JW, Moore TM, Wilson PS, Ballard ST, Taylor AE. Vascular permeability and epithelial transport effects on lung edema formation in ischemia and reperfusion. J Appl Physiol (1985) 1994;77:1116-1121.
31. Palmieri TL, Enkhbaatar P, Bayliss R, Traber LD, Cox RA, Hawkins HK, et al. Continuous nebulized albuterol attenuates acute lung injury in an ovine model of combined burn and smoke inhalation. Crit Care Med 2006;34:1719-1724.
32. McAuley DF, Frank JA, Fang X, Matthay MA. Clinically relevant concentrations of b2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med 2004;32:1470-1476.
33. Perkins GD, McAuley DF, Thickett DR, Gao F. The Beta-Agonist Lung Injury Trial (BALTI): A randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006;173:281-287.
34. Béduneau G, Pham T, Schortgen F, Piquilloud L, Zogheib E, Jonas M, et al.; WIND (Weaning according to a New Definition) Study Group and the REVA (Réseau Européen de Recherche en Ventilation Artificielle) Network. Epidemiology of weaning outcome according to a new definition: The WIND study. Am J Respir Crit Care Med 2017; 195:772-783.
35. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
36. Hauck WW, Anderson S, Marcus SM. Should we adjust for covariates in nonlinear regression analyses of randomized trials?. Control Clin Trials 1998;19:249-256.
37. Raab GM, Day S, Sales J. How to select covariates to include in the analysis of a clinical trial. Control Clin Trials 2000;21:330-342.
38. Steingrimsson JA, Hanley DF, Rosenblum M. Improving precision by adjusting for prognostic baseline variables in randomized trials with binary outcomes, without regression model assumptions. Contemp Clin Trials 2017;54:18-24.
39. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al.; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive endexpiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004;351:327-336.
40. Thille AW, Richard JC, Brochard L. The decision to extubate in the intensive care unit. Am J Respir Crit Care Med 2013;187:1294-1302.
41. Ruan SY, Teng NC, Wu HD, Tsai SL, Wang CY, Wu CP, et al. Durability of weaning success for liberation from invasive mechanical ventilation: An analysis of a nationwide database. Am J Respir Crit Care Med 2017;196:792-795.
42. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, et al.; Pediatric Acute Lung Injury and Sepsis Investigators. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: A randomized controlled trial. JAMA 2005;293:470-476.
43. Curley MA, Hibberd PL, Fineman LD, Wypij D, Shih MC, Thompson JE, et al. Effect of prone positioning on clinical outcomes in children with acute lung injury: A randomized controlled trial. JAMA 2005;294: 229-237.
44. Bein T, Weber-Carstens S, Goldmann A, Müller T, Staudinger T, Brederlau J, et al. Lower tidal volume strategy (_3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: The prospective randomized Xtravent-study. Intensive Care Med 2013;39:847-856.
45. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al.; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018;378: 809-818.
46. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al.; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362: 779-789.
47. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al.; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358: 877-887.
48. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al.; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial. JAMA 2016; 316:509-518.
49. Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, et al.; SMART Investigators and the Pragmatic Critical Care Research Group. Balanced crystalloids versus saline in critically ill adults. N Engl J Med 2018;378:829-839.
50. Page VJ, Casarin A, Ely EW, Zhao XB, McDowell C, Murphy L, et al. Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): A randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2017;5:727-737.
51. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al.; BLING II Investigators for the ANZICS Clinical Trials Group. A multicenter randomized trial of continuous versus intermittent b-lactam infusion in severe sepsis. Am J Respir Crit Care Med 2015; 192:1298-1305.
52. Agus MS, Wypij D, Hirshberg EL, Srinivasan V, Faustino EV, Luckett PM, et al.; HALF-PINT Study Investigators and the PALISI Network. Tight glycemic control in critically ill children. N Engl J Med 2017;376: 729-741.
53. Self WH, Semler MW, Wanderer JP, Wang L, Byrne DW, Collins SP, et al.; SALT-ED Investigators. Balanced crystalloids versus saline in noncritically ill adults. N Engl J Med 2018;378:819-828.